It anticipates using the funds to complete the development of its first set of diagnostic products, and for a set of clinical studies to obtain regulatory clearance.
As part of the collaboration, Johnson & Johnson will build a lung cancer center at Boston University and build upon programs linked to cancer research.
The deal follows the release of a report that, among other things, urged support for genomics and other life sciences in the UK.
The firm’s emphasis on automation has yielded Dx products for blood banks, assays for HIV and acute kidney injury, and flexible diagnostic test systems that can adapt to labs’ changing needs.
The companies will work to develop an affordable, portable, and easy-to-use HIV quantitative viral load test using Cue's Lab-In-A-Box MDx platform.
Johnson & Johnson announced that it would be cutting about 3,000 jobs from its medical devices section.
Using J&J's CellSearch platform, researchers have demonstrated the expression of PD-L1 on CTCs, a finding they believe they are the first to show.
Three new assays were presented in posters at April's Clinical Virology Symposium.
IBM and its partners look to combine health information to develop a health platform for the Watson supercomputer.
Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.
Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.
In Science this week: research regulation and reporting requirement reform, and more.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.